Continuous erythropoietin receptor activator clinical trials
Also written Methoxy polyethylene glycol-epoetin beta, Mircera, R744 and RO0503821.
How each study uses continuous erythropoietin receptor activator is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 14 Nov 2007 · MIRCERA · BLA 125164 (FDA, Drugs@FDA)
- European Union
- 20 Jul 2007 · Mircera · EMEA/H/C/000739 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
71 studies that test it; most in 2007 (21)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 2 |
| 2004 | 7 |
| 2006 | 2 |
| 2007 | 21 |
| 2008 | 21 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 68 · Other 3
Hoffmann-La Roche (61) · Chugai Pharmaceutical (6) · Hamad Medical Corporation (1) · Taipei Veterans General Hospital, Taiwan (1) · University Hospital, Basel, Switzerland (1) · Samsung Medical Center (1)
Studies
Open first, then newest update. How each study uses continuous erythropoietin receptor activator is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 71
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.CompletedPhase 3Hoffmann-La RocheNCT00560404Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.CompletedPhase 3Hoffmann-La RocheNCT00661388Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.CompletedPhase 2Hoffmann-La RocheNCT03552393Written as MirceraHow we know
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on DialysisCompletedPhase 3Hoffmann-La RocheNCT00642967Written as Methoxy Polyethylene Glycol-epoetin BetaHow we know
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.CompletedPhase 3Hoffmann-La RocheNCT00717821Written as Methoxy Polyethylene Glycol-epoetin BetaHow we know
- A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)CompletedPhase 4Hoffmann-La RocheNCT00773513Written as methoxy polyethylene glycol-epoetin betaHow we know
- A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or DialysisCompletedPhase 4Hoffmann-La RocheNCT01519947Written as Methoxy polyethylene glycol-epoetin betaHow we know
- A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic NephropathyCompletedPhase 4Hoffmann-La RocheNCT01191983Written as Methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.CompletedPhase 3Hoffmann-La RocheNCT00642304Written as methoxy polyethylene glycol-epoetin beta [C.E.R.A.]How we know
- A Study of Mircera in Anemic Patients With Multiple MyelomaCompletedPhase 1/2Hoffmann-La RocheNCT00360347Written as C.E.R.A.How we know
- A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.CompletedPhase 2Hoffmann-La RocheNCT00048048Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.CompletedPhase 4Hoffmann-La RocheNCT00737464Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal AnemiaCompletedPhase 3Hoffmann-La RocheNCT00661505Written as methoxy polyethylene glycol-epoetin betaHow we know
- A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal AnaemiaTerminatedPhase 4Hoffmann-La RocheNCT01066000Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- Comparison Among Erythropoietin Stimulating AgentsCompletedPhase 4Hamad Medical CorporationNCT02049346Written as Methoxy polyethylene glycol-epoetin betaHow we know
- Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on HemodialysisCompletedPhase 2Hoffmann-La RocheNCT00717366Written as Methoxy Polyethylene Glycol-Epoetin BetaHow we know
- A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on DialysisCompletedPhase 4Hoffmann-La RocheNCT00922116Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal AnemiaCompletedPhase 4Hoffmann-La RocheNCT01342640Written as methoxy polyethylene glycol-epoetin beta [Mircera]How we know
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal AnemiaCompletedPhase 4Hoffmann-La RocheNCT00642668Written as methoxy polyethylene glycol-epoetin betaHow we know
- A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal DialysisCompletedPhase 3Hoffmann-La RocheNCT00737477Written as Methoxy polyethylene glycol-epoetin betaHow we know
See all 71 studies that test continuous erythropoietin receptor activator →
Given beside what is tested · 1 — continuous erythropoietin receptor activator is usual care or a partner of the new treatment
As the comparator · 6 — what is tested is compared with continuous erythropoietin receptor activator
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisActive, not recruitingPhase 3BiocadNCT07119372Written as Mircera (methoxypolyethylene glycol-epoetin beta)How we know
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCompletedPhase 3Akebia TherapeuticsNCT04707768Written as Mircera®How we know
- Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal AnemiaCompletedPhase 3GlaxoSmithKlineNCT02791763Written as Epoetin beta pegolHow we know
- Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on DialysisCompletedPhase 2BiocadNCT03519243Written as MirceraHow we know
- Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy VolunteersCompletedPhase 1BiocadNCT02731469Written as Mircera®How we know
- Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)CompletedPhase 2Genexine, Inc.NCT02044653Written as MIRCERAHow we know
Codes
What other systems call continuous erythropoietin receptor activator · ClinicalTrials.gg INT004878
- RxNorm 729596One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 729596 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.